The hematoma phase is characterized by the release of pro-inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6), which recruit neutrophils and macrophages to the fracture site. The gene discussed is IL6; the disease is hematoma.